- Teva launches authorized generic version of Pfizer's Detrol LA
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- Americans more likely than others to prefer generics, study finds
- Teva launches generic drug for cystic fibrosis patients
- State of the market: Are generic drugs approaching their peak?
JERUSALEM Teva Pharmaceutical Industries got closer to finishing its $5 billion acquisition of German drug maker Ratiopharm from the Merckle Group, the Israeli generic drug manufacturer said Tuesday.
Teva announced that the European Commission approved its plan to acquire Ratiopharm. The Competition Bureau of Canada had said Friday that it would not challenge the acquisition.
Ratiopharm was put up for sale last year following the suicide of its owner, Adolf Merckle, who left behind crushing debts for the generic drug maker and Phoenix Pharmahandel & Co., the family’s drug-distribution business.